about
Lithium for schizophreniaHaloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disordersFlupenthixol versus low-potency first-generation antipsychotic drugs for schizophreniaCarbamazepine for schizophreniaTrifluoperazine versus low-potency first-generation antipsychotic drugs for schizophreniaBenzodiazepines for schizophreniaHaloperidol versus first generation antipsychotics for schizophreniaFlupenthixol versus low-potency first generation antipsychotic drugs for schizophreniaTrifluoperazine versus low-potency first generation antipsychotic drugs for schizophreniaPutting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analysesDiscontinuous patterns of brain activation in the psychotherapy process of obsessive-compulsive disorder: converging results from repeated FMRI and daily self-reports[Neuroimaging the various symptom dimensions of obsessive-compulsive disorder].Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses.Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials.Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective.The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes - Results from a cross-sectional European multicenter study.Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.Evidence-based pharmacotherapy of treatment-resistant unipolar depression.Increasing placebo response in antipsychotic trials: a clinical perspective.Dose escalation of antipsychotic drugs in schizophrenia: a meta-analysis of randomized controlled trials.Factors contributing to the increasing placebo response in antidepressant trials.Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers - A pharmacoepidemiological cross-sectional multicenter study.Low comorbid obsessive-compulsive disorder in patients with major depressive disorder - Findings from a European multicenter study.Dose Escalation of Antidepressants in Unipolar Depression: A Meta-Analysis of Double-Blind, Randomized Controlled Trials.Robust Antidepressant Effect Following Alternating Intravenous Racemic Ketamine and Electroconvulsive Therapy in Treatment-Resistant Depression: A Case Report.Second-Generation Antipsychotic Drugs in Anorexia Nervosa: A Meta-Analysis of Randomized Controlled TrialsEffektivität einer Augmentationstherapie mit Antipsychotika bei therapieresistenten Zwangsstörungen – eine Metaanalyse doppelblinder, randomisierter, placebokontrollierter StudienClinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter studyBeeinflussung des Behandlungsergebnisses einer stationären Psychotherapie von Zwangsstörungen durch den Ausprägungsgrad der Instabilität im Therapieverlauf
P50
Q24186325-35A650BC-F317-4092-BDB5-D704B6413D33Q24186601-7EA9C406-8374-4BE9-A14F-3E4C4E52BDA3Q24193881-EC571608-14AD-47A3-8FC7-C0BB6C9395BAQ24194779-23AA98A8-C24B-4D80-8CBD-8472A9935E66Q24194898-E9BC06CE-2E28-4FEA-B791-F8CEB72153ABQ24197501-56DEE29F-AD3A-4B7C-A0A2-484332CB38F0Q24198264-97599B86-54AE-4494-921A-DE3DA28A6D00Q24235116-D2FBC52E-BFD9-4987-9616-0D7B0F4C8B72Q24236681-89A92FDF-FA91-4208-94AB-80EE02AC13BDQ26853468-F0F348A0-5867-45CE-96A3-1D6EE75C22ECQ30450424-7A47FE7E-D306-44D5-BA2C-813B55472B76Q33515856-E1511266-C63D-49F5-8AFC-556957F96AF5Q34296626-5AEAFB4A-1243-4B57-996B-A81B24C26785Q35161991-2905753B-5791-42DC-8947-0E4FD4C19B84Q36077216-D6B2BE13-28B5-4F74-B7F9-37C113AA1A9DQ38100474-F48E2C44-93D7-4C44-A603-96C3701794AFQ38203063-EEC2AB49-8C20-416C-977B-B5762627C198Q38745972-95C5655F-B046-436E-9522-82AB2E869C40Q38912452-9AA4FEB7-9AB7-4E76-8540-55566D22CAA1Q39009865-B080CDF3-8087-4519-8C22-3D15E1E81A90Q40783366-0D02D7CE-8F41-46AE-9887-83A2D1625471Q40904206-6428A44E-A1BB-4E7D-88F0-50C4B42297A7Q41411906-9B981785-F877-4E8C-BD78-B4AEC991B29CQ47637703-BDC1DD06-8362-456C-8BEC-998BC1D22437Q47717780-4DE6A9FC-966C-4F35-88A5-A6DAAC40E216Q47770326-109E5F1A-BEAE-4390-81ED-D38D787E0294Q53739677-8625663C-727D-485E-B504-D89FDCA814EDQ53739677-F33D2C9D-96AD-473C-A5B0-4D0FA63BB963Q57737987-1B7B34B9-F600-4B99-9BEC-CE2608E140A8Q57738294-27F21783-77C0-4357-B068-95731133AC6EQ60627918-18F72BE7-4152-46CD-B0F9-6CDE2220007BQ60646387-A7A62169-5CC7-4586-9250-9C2A50D06E94
P50
description
researcher ORCID: 0000-0002-0266-0083
@en
wetenschapper
@nl
name
Markus Dold
@ast
Markus Dold
@en
Markus Dold
@es
Markus Dold
@nl
Markus Dold
@sl
type
label
Markus Dold
@ast
Markus Dold
@en
Markus Dold
@es
Markus Dold
@nl
Markus Dold
@sl
prefLabel
Markus Dold
@ast
Markus Dold
@en
Markus Dold
@es
Markus Dold
@nl
Markus Dold
@sl
P106
P21
P31
P496
0000-0002-0266-0083